Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
CA 2386955 A1 · Owner: Toogood, Peter Laurence · Inventors: Singh, Rajeshwar; Winters, Roy Thomas; Dobrusin, Ellen Myra
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention provides quinazolines that are useful for treating cell proliferative diseases and disorders, such as cardiovascular diseases infections, cancers, autoimmune diseases gout, kidney disease, and , neurodegenerative diseases and disorders such as Alzheimer's disease. We have now discovered a group of 2-arylamino-quinazolines (I) and (II) that are potent inhibitors of cyclin-dependent kinases (cdks). The compounds are readily synthesized and can be administered by a variety of routes including , orally, and have sufficient bioavailability. This invention also provides pharmaceutical formulations comprising at least one of the quinazoline compounds together with a …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 3, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended November 3, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 3, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.